The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma

Hye Ryun Kim(Yonsei University), Byoung Chul Cho(Yonsei University), Ross A. Soo(National University Cancer Institute, Singapore), Susan Jewell(Netherlands Institute for Radio Astronomy), Eun‐Joo Shin, J. K. Park, Soohyun Hwang, Jihun Kim(Chungbuk National University), H. J. Kim(Yonsei University), J. Wang, Dae Ryong Kang(Yonsei University), Seungtaek Lim(Yonsei University), M. Bae(Yonsei University), Herbert Haack(Cell Signaling Technology (United States)), S.-H.I. Ou(University of California, Irvine Medical Center), Hyo Sup Shim(Yonsei University)
Annals of Oncology
June 21, 2013
10.1093/annonc/mdt220
Cited by 125

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565